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Inﬂammasome signaling affects anxiety- and depressive-like
behavior and gut microbiome composition
M-L Wong1,2,9,10, A Inserra1,2,9, MD Lewis1,2, CA Mastronardi3, L Leong4,5, J Choo4,5, S Kentish6, P Xie7,10, M Morrison8, SL Wesselingh4,5,
GB Rogers4,5,10 and J Licinio1,2,10
The inﬂammasome is hypothesized to be a key mediator of the response to physiological and psychological stressors, and its
dysregulation may be implicated in major depressive disorder. Inﬂammasome activation causes the maturation of caspase-1 and
activation of interleukin (IL)-1β and IL-18, two proinﬂammatory cytokines involved in neuroimmunomodulation, neuroinﬂammation
and neurodegeneration. In this study, C57BL/6 mice with genetic deﬁciency or pharmacological inhibition of caspase-1 were
screened for anxiety- and depressive-like behaviors, and locomotion at baseline and after chronic stress. We found that genetic
deﬁciency of caspase-1 decreased depressive- and anxiety-like behaviors, and conversely increased locomotor activity and skills.
Caspase-1 deﬁciency also prevented the exacerbation of depressive-like behaviors following chronic stress. Furthermore,
pharmacological caspase-1 antagonism with minocycline ameliorated stress-induced depressive-like behavior in wild-type mice.
Interestingly, chronic stress or pharmacological inhibition of caspase-1 per se altered the fecal microbiome in a very similar manner.
When stressed mice were treated with minocycline, the observed gut microbiota changes included increase in relative abundance
of Akkermansia spp. and Blautia spp., which are compatible with beneﬁcial effects of attenuated inﬂammation and rebalance of gut
microbiota, respectively, and the increment in Lachnospiracea abundance was consistent with microbiota changes of caspase-1
deﬁciency. Our results suggest that the protective effect of caspase-1 inhibition involves the modulation of the relationship
between stress and gut microbiota composition, and establishes the basis for a gut microbiota–inﬂammasome–brain axis, whereby
the gut microbiota via inﬂammasome signaling modulate pathways that will alter brain function, and affect depressive- and
anxiety-like behaviors. Our data also suggest that further elucidation of the gut microbiota–inﬂammasome–brain axis may offer
novel therapeutic targets for psychiatric disorders.
Molecular Psychiatry (2016) 21, 797–805; doi:10.1038/mp.2016.46; published online 19 April 2016
INTRODUCTION
Increasing evidence suggests an involvement of neuroinﬂamma-
tory pathways in the etiopathophysiology of major depressive
disorder (MDD) and antidepressant response.1,2 Depressive
symptoms are underlined by increased levels of proinﬂammatory
cytokines (that is, interleukin (IL)-1β and IL-6), decreased levels of
anti-inﬂammatory cytokines (that is, IL-4 and IL-10) and are
associated with polymorphisms in inﬂammation-related genes.3–5
IL-1 receptor type-I and its ligands are expressed in brain areas
relevant to stress response,6–8 and IL-1β signaling is fundamental
in mediating the deleterious neurobehavioral and neuroendocrine
responses to stress and adaptation.9,10 Chronic stress or IL-1β
administration triggers depressive-like behavior.11
A variety of stressors activate the inﬂammasome through the
NLRP3 or P2X7 receptors, resulting in caspase-1 maturation that
processes and releases bioactive IL-1β and IL-18.12,13 Caspase-1 and
NLRP3 mRNA are increased in blood cells of depressed patients,14
suggesting that the inﬂammasome is a key mediator by which
physical and psychological stressors contribute to the development
of depression, leading to the ‘inﬂammasome hypothesis’ of depres-
sion.15 If that proves to be correct, caspase-1 inhibiting compounds
may have antidepressant effects. Minocycline is a semisynthetic
tetracycline antibiotic that inhibits caspase-1 and caspase-3 trans-
cription and has anti-apoptotic, anti-inﬂammatory and neuroprotec-
tive properties as well as acute antidepressant-like effects.16–22
Caspase-1 knockout (casp1− /−) mice are overtly normal, despite
having undetectable IL-1β and low IL-1α levels.23 They have
decreased systemic inﬂammatory response and increased survival
to lethal endotoxin doses when compared with wild-type (wt)
mice.23,24 This is underlined by reduced inﬂammation-induced
brain transcription, decreased inﬂammasome assembly and
consequently decreased circulating IL-1β and IL-18.23,24
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The microbiota–gut–brain axis is a complex multiorgan bidirec-
tional signaling system between the microbiota and the brain that
plays a fundamental role in host physiology, homeostasis,
development and metabolism.25 Growing evidence shows repro-
ducible and consistent effects of microbial states on mouse
behavior, supporting a role for microbiota in modulating
behavior.26–28 Differences in anxiety-related behaviors are com-
monly reported in mice with altered gut microbiomes, implicating
the role of gut microbiota in stress and depression.29,30 Casp1− /−
mice display depressive-like behavior and anorexia after periph-
eral but not central LPS administration and differ in gut microbiota
composition compared with wt mice.31–33 Therefore, our primary
and secondary hypotheses were, respectively, (1) that decreased
caspase-1 activity would result in decreased depressive-like
behavior and (2) that caspase-1 inhibition using intraperitoneal
minocycline administration and chronic restraint stress would
result in changes in the gut microbiome. The null hypothesis was
that there would be no difference in these parameters between
casp1− /−, wt and minocycline-treated mice.
MATERIALS AND METHODS
Procedures were approved by the Animal Ethics Committees of the
Australian National University and the South Australian Health and Medical
Research and are in accordance with the Australian Code for the Care and
Use of Animals for Scientiﬁc Purposes (8th edition, 2013). Male mice
(C57BL/6J background, wt, n= 81; casp1− /−, n= 20) aged 60–90 days were
obtained from the Australian Phenomics (Canberra, ACT, Australia) or the
Bioresources Facilities (Adelaide, SA, Australia). Genetic caspase-1 deﬁ-
ciency was conﬁrmed by genotyping in experimental mice (Supplementary
Figure S1). Littermates were group housed (Green Line IVC Sealsafe PLUS
mouse, Tecniplast, Varese, Italy) in a temperature-speciﬁc (22C± 1 °C) and
light-speciﬁc (12 h cycles, lights on at 0700 h) pathogen-free room
with water and standard regular chow ad libitum. Animals were assigned
and randomized as described in the Supplementary Materials and
Methods. The investigators were not blinded to group assignment.
Behavioral phenotyping was performed between 0900 h and
1600 h. Animals were given 30 min of habituation to the behavioral
testing room. Tests were performed from the least to the most invasive
to minimize the inﬂuence of prior test history (in order: rotarod, elevated
plus maze, marble burying test, open ﬁeld test, sucrose preference test,
novelty suppressed feeding and forced swim test; see Supplementary
Materials and Methods for details).34 Following chronic restraint stress this
order was reversed for a bell-shaped stress exposure (Supplementary
Figure S2).
Chronic restraint stress
After baseline behavioral testing, animals were submitted to restraint stress
for 21 days. Every day, mice were placed in a horizontal resting position
inside a well-ventilated (12 holes, 0.5 mm diameter) 50 ml falcon tube at
1000 h and after 4–6 h they were unrestrained.
Pharmacological caspase-1 inhibition with minocycline
The wt animals were treated with either saline (0.2 ml, intraperitoneally,
n= 27) or minocycline (LKT Laboratories, St Paul, MN, USA; 5 mg kg− 1
per day in 10 ml kg− 1 saline, intraperitoneally, n=27). Treatment lasted for
the same duration of the restraint procedure (21 days).
Respirometry
Minocycline- or saline-treated restrained animals were individually housed
in the Promethion Metabolic Monitoring System (Sable Systems Interna-
tional, Las Vegas, NV, USA) for 48 h to assess the effects of minocycline on
exploratory behavior, food intake, energy expenditure and volume of
oxygen inhaled and of carbon dioxide exhaled at baseline and after
chronic restraint.
16S rRNA analysis
Please see Supplementary Materials and Methods for a detailed explanation
of the methods used for the 16S rRNA analysis. Brieﬂy, fecal pellets were
collected with autoclaved toothpicks, placed in 1.5 ml tubes, snap-frozen on
dry ice and stored at − 80 °C. Following DNA extraction, fecal microbiota
proﬁling was performed by paired-end 16S rRNA gene amplicon
sequencing, based on the Illumina MiSeq platform (Australia and New
Zealand, VIC, Australia) to a depth of ∼ 40 000 reads per sample. Sequence
data processing was performed as previously described.35
Statistical analysis
Statistical analyses were performed using the Statistical Package for the
Social Sciences version 22.0 for Windows (SPSS, Chicago, IL, USA) using a
general linear model for repeated measures. The effects of genotype,
stress, treatment and their interaction were explored and the signiﬁcance
set at Po0.05. Sphericity of the variances of the groups was assessed with
Mauchly’s sphericity test. If the assumption of sphericity was violated, the
Greenhouse–Geisser correction was generated. Effect size was reported as
partial eta-squared (η2p). Signiﬁcant stress × genotype or stress × treatment
interaction was unpacked as described previously.36 Comparison of
microbiota composition between groups (β-diversity) was performed
using Bray–Curtis similarity matrices in PRIMER (v6, PRIMER-E, Plymouth,
UK). Matrices were generated from sample-normalized, square-root
transformed, relative operational taxonomic unit abundance.
Community-level changes were assessed for signiﬁcance using one-way
permutational multivariate analyses of variance (PERMANOVA) tests with
9999 random permutations and at a signiﬁcance threshold of Po0.01. The
contribution of individual taxa to between-group variation was assessed by
similarity percentage analysis, as previously reported.37 Where speciﬁc
bacterial taxa were identiﬁed as contributing to change in microbiota
composition, variation in their relative abundance was further assessed
through Mann–Whitney U-tests between groups. Differences of median
relative abundance between groups were assessed using Hodges–
Lehmann estimator.
RESULTS
Our primary outcome measure was the assessment of depressive-
like behavior in the forced swim test. Secondary outcome
measures included anxiety-like behavior, changes in the sucrose
preference test, locomotor activity, gut microbiome and respiro-
metry. Analyses and results of behavioral tests results are available
in Supplementary Tables S1–S3.
Caspase-1 deﬁciency decreases depressive and anxiety-like
behaviors
Our results showed that caspase-1 deﬁciency decreased depres-
sive- and anxiety-like behaviors. In the forced swim test, the
total ﬂoating time was lower in casp1− /− compared with wt
mice (F1, 45 = 117.04, Po0.0001, Figure 1a and Supplementary
Table S1). At the same time, swimming and climbing behaviors
were higher in casp1− /− mice compared with wt (respectively
F1, 45 = 117.10, Po0.0001, and F1, 45 = 38.69, Po0.0001). Anxiety-
like behaviors had a signiﬁcant main effect of genotype in 4 tests:
(1) elevated plus maze, (2) novelty suppressed feeding, (3) marble
burying and (4) open ﬁeld tests. We found a signiﬁcant main
effect of genotype in the elevated plus maze open to closed arms
time ratio (F1, 45 = 4.16, P= 0.047, Figure 1b), indicating an
anxiolytic phenotype in casp1− /− mice. Accordingly, in the novelty
suppressed feeding, casp1− /− mice showed decreased latency to
eat in a novel environment following fasting (F1, 43 = 32.17,
Po0.0001, Figure 1c). In the marble burying test, which
is considered predictive of anxiolytic compounds,38 we observed
a decreased number of marbles buried by casp1− /− mice
(F1, 45 = 11.55, P= 0.001, Figure 1d). Moreover, casp1
− /− mice
displayed a decreased number of fecal boli during the open ﬁeld
test (F1, 45 = 4.72, P = 0.035, Figure 1e), whereas no differences
were observed for the time spent in the center area of the arena,
another measure of anxiety-related behavior (F1, 45 = 0.05,
P= 0.826). In the sucrose preference test, casp1− /− mice displayed
an increased preference for a 1% sucrose solution (F1, 33 = 5.52,
P= 0.025, Supplementary Table S1), suggesting greater hedonic
behavior.
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Caspase-1 deﬁciency affects chronic restraint stress response
Our results suggest that casp-1− /−mice had an attenuated response
to chronic stress. We found a signiﬁcant (genotype× stress)
interaction for swimming and climbing time in the forced swim
test (respectively F1, 45 = 7.02, P= 0.011, and F1, 45 = 8.60, P= 0.005).
The wt mice showed a greater decrease in swimming time (70%,
F1, 45 = 45.48, Po0.0001) than casp1− /− mice (14%, F1, 45 = 5.33,
P= 0.026) following stress. Accordingly, wt animals displayed a
greater reduction in climbing time (91%, F1, 45 = 33.33, Po0.0001)
compared with casp1− /− mice (64%, F1, 45 = 78.13, Po0.0001)
following restraint (Figure 1a). We found a signiﬁcant (genotype×
stress) interaction for body weight changes (F1, 45 = 6.06, P= 0.018)
that decreased in wt mice following restraint (F1, 45 = 14.24,
Po0.0001, average Δ body weight =− 1.3 g) but remained
unchanged in casp1− /− mice (F1, 45 = 0, P= 1, average Δ body
weight= 0 g). Furthermore, we found a signiﬁcant (genotype×
stress) interaction in the number of defecations in the open ﬁeld
test (F1, 45 = 30.93, Po0.0001, Figure 1d); casp1− /− mice did not
show an increase in this parameter following restraint (F1, 45 = 1.73,
P= 0.196) whereas wt mice did (F1, 45 = 48.98, Po0.0001).
Caspase-1 deﬁciency increases locomotion and locomotor skills
We found that caspase-1 deﬁciency increases locomotor activity in
the open ﬁeld test (F1, 45 = 10.54, P = 0.002, Figure 2a). Moreover,
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Figure 1. Caspase-1 (casp1) deﬁciency decreases anxiety-like and depressive like behavior and affects chronic restraint stress response.
(a) Casp1 knockout (casp1− /−) mice displayed decreased ﬂoating time in the forced swim test in comparison with wild-type (wt) mice and
(b) displayed decreased anxiety-like behavior as measured by the open/closed arms time ratio in the elevated plus maze. (c) In the novelty
suppressed feeding test, casp1− /− mice showed signiﬁcantly decreased latency to feed following 16 h of fasting but not water deprivation.
(d) Moreover, casp1 deﬁciency resulted in less marbles buried in the marble burying test. (e) In the open ﬁeld test, we observed a decreased
number of fecal boli as a result of casp1 deﬁciency as well as a different response to chronic restraint stress. Data are presented as mean±
s.e.m. Genotype effect: *Po0.05, **Po0.01, ****Po0.0001; stress effect: +Po0.05, ++Po0.01, ++++Po0.0001; genotype × stress effect:
####Po0.0001. BL, baseline; STR, after chronic restraint stress paradigm; wt, wild type.
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casp1− /− mice acquired skills more quickly than wt mice to
perform in the accelerating rotarod test (F1, 45 = 15.35, Po0.0001,
Figure 2b and Supplementary Table S2).
Chronic restraint stress increases anxiety-like and depressive-like
behaviors
Chronic restraint stress (4–6 h per day for 21 days) increased the
ﬂoating time in the forced swim test (F1, 45 =66.92, Po0.0001,
Figure 1a), whereas it decreased swimming (F1, 45 =37.80, Po0.0001)
and climbing behavior (F1, 45 =109.52, Po0.0001). It also increased
anxiety-like behavior in the elevated plus maze test, decreasing the
time spent in the open arms (F1, 45= 5.65, P=0.022) and the open to
closed arms time ratio (F1, 45 =4.55, P=0.038, Figure 1b), as well as in
the open ﬁeld test, increasing the number of defecations
(F1, 45 =12.74, P=0.001, Figure 1e). Furthermore, restraint decreased
body weight gain (F1, 45 =6.06, P=0.018) and food intake
(F1, 43 =5.75, P=0.021). Nevertheless, restrained mice showed an
increase in ratio quotient (F1, 28 =4.79, P=0.037). Following restraint,
no changes were observed in the sucrose preference test
(F1, 33 =0.05, P=0.817, Supplementary Table S1) or in locomotor
activity in the open ﬁeld test (F1, 45 = 3.64, P= 0.063, Figure 2a).
Minocycline treatment affects stress response and metabolic
parameters
We found a signiﬁcant (treatment × stress) interaction in the
ﬂoating time in the forced swim test (F1, 28 = 6.67, P = 0.015,
Figure 3a and Supplementary Table S3). Saline- and minocycline-
treated animals displayed similar ﬂoating times at baseline
(F1, 28 = 2.35, P = 0.137); however, minocycline-treated mice were
less immobile than saline-treated mice following restraint
(F1, 28 = 5.25, P = 0.030). No differences were observed between
restrained mice receiving saline or minocycline in locomotion,
food intake, energy expenditure, body mass and volume of
oxygen inhaled (not shown). We found a signiﬁcant effect of
treatment and stress on the volume of carbon dioxide exhaled
(respectively F1, 28 = 5.64, P = 0.025 and F1, 28 = 8.13, P= 0.008,
Figure 3b).
Chronic restraint stress affects the gut microbiome
Chronic restraint stress (4–6 h per day for 21 days) affected the gut
microbiome compared with nonstressed animals (PERMANOVA
P= 0.0027, t= 2.3492). Although the shallowest level of classiﬁca-
tion (that is, phylum level) only revealed a nonsigniﬁcant trend
toward an increased ratio of Firmicutes to Bacteroidetes
(Figure 4a), the deeper analysis did identify clear differences
between the animal groups. In particular, the relative abundances
of the genera Allobaculum (difference in median relative
abundance − 7.8%, Po0.0001 Mann–Whitney U-test), Biﬁdobac-
terium (−4.6%, P= 0.0002), Turicibacter (−3.4%, Po0.0007),
Clostridium (−0.7%, Po0.0001) and the family S24-7 (−5.8%,
P= 0.0021) were all reduced in restrained animals, and the relative
abundance of the family Lachnospiraceae was increased (+0.3%,
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Figure 2. Caspase-1 (casp1) deﬁciency increases spontaneous locomotion and locomotory skills. (a) Casp1 knockout (casp1− /−) mice had
increased locomotor activity in the open ﬁeld test when compared with wild-type (wt) mice and (b) acquired quicker the skills to perform the
rotarod test. Data are mean± s.e.m. Genotype effect: Po0.05; **Po0.01; ****Po0.0001. BL, baseline; STR, after chronic restraint stress
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Figure 3. Caspase-1 antagonism affects chronic restraint stress response. (a) Minocycline treatment (mino) in wild-type (wt) animals during
chronic restraint stress (STR) prevented stress-induced increased ﬂoating time in the forced swim test. (b) Respirometry measurement for
volume of CO2 exhaled revealed a signiﬁcant effect of stress as well as treatment. Data are mean± s.e.m. Treatment effect: *Po0.05; stress
effect: ++Po0.01; treatment × stress effect: #Po0.05. BL, baseline.
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P= 0.0244). Variance in the relative abundance of these taxa
accounted for 440% of intergroup variance.
Minocycline affects the gut microbiome
Minocycline treatment (5 mg kg− 1 per day for 21 days) also
affected microbiota composition compared with saline-treated
controls (PERMANOVA P = 0.0001, t= 3.0947, Figure 4b) and,
interestingly, in a manner very similar to that observed for
restrained animals. In particular, minocycline-treated animals
were also found to possess lower relative abundances of the
genera Allobaculum (difference in median relative abundance
− 7.8%, Po0.0001 Mann–Whitney U-test), Biﬁdobacterium (−5.8%,
Po0.001), Turicibacter (−4.2%, Po0.0001), Clostridium (−0.7%,
Po0.0001) and the family S24-7 (−7.4%, P = 0.003), and signiﬁ-
cantly high relative abundances of the family Lachnospiraceae
(+25.3%, P= 0.005) and Ruminococcaceae incertae sedis (+2.4%,
P= 0.024). Variance in the relative abundance of these taxa
accounted for 467% of intergroup variance.
Effect of chronic restraint stress on the gut microbiome in
combination with minocycline
Combining chronic restraint with minocycline treatment resulted
in a microbiota composition that was different to that of
nonrestrained saline-treated controls (PERMANOVA P = 0.0002,
t= 3.4593, Figure 4b). There were also no signiﬁcant differences
in the shallow, phylum-level proﬁles produced from mice receiv-
ing each treatment alone or in combination (using a PERMANOVA
threshold of Po0.01), and at deeper levels of analysis, the signiﬁ-
cant reductions in the relative abundances of both Turicibacter
and Biﬁdobacterium spp. were also observed in mice receiving
Figure 4. Minocycline treatment and chronic restraint stress affect the gut microbiome and chronic restraint stress changes the gut
Firmicutes/Bacteroidetes (F/B) ratio. (a) Box and whiskers plot displayed the analysis of the differences of the main composition of the
microbiota (Firmicutes to Bacteroidetes). Upper and lower quartiles deﬁned the box with median midline, and the whiskers were assessed
using Tukey’s method. (b) Microbiota distribution at species level of taxon contributing to 97.5% of sample variations. Heatmap shows square
root-transformed read counts for the 20 taxa determined by similarity percentage analysis. The dendrogram shows the clustering of genera
based on Ward’s hierarchical clustering method. Phyla are abbreviated as follows: Actinobacteria (A), Bacteroidetes (B), Firmicutes (F),
Proteobacteria (P) and Verrocomicrobia (V).
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both treatments (Figures 5a and b), as was the increase in
members of the Lachnospiraceae (Figure 5e). Additional changes
in the microbiome proﬁles not observed with either treatment
alone were found when restraint and minocycline were used
together. For example, the relative abundances of Akkermansia
spp. and Blautia spp. were increased (Figures 5d and e).
Minocycline also appears to have a stronger effect on the relative
abundances of Lactobacillus spp. and Anaerovorax spp., with
relatively greater abundances of these genera observed in the
restrained animals, but reductions in their relative abundances
when minocycline was also administered (Figures 5f and g).
DISCUSSION
Caspase-1 is a cysteine protease that cleaves pro-IL-1β and
pro-IL-18 into their mature isoforms in the NLRP3 inﬂammasome
in response to stressful stimuli such as psychosocial and microbial
stress, adenosine triphosphate, toxins and particulate matter.13,39
Because casp1− /− mice lack caspase-1 mRNA and its mature
protein product, they have decreased inﬂammasome bioactivity
and inﬂammasome-driven IL-1β and IL-18 production, and could
be helpful in identifying the role of caspase-1 in behavior, via
either innate or after stress-induced inﬂammasome activation.23
Our data highlight a role for caspase-1 in the modulation of innate
behavior as well as in the response to chronic stress, as caspase-1
modulation decreased baseline anxiety- and depressive-like
behaviors, as well as the exacerbation of depressive-like behaviors
following chronic restraint stress. Our results are in line with
studies reporting that modulation of the IL-1β axis is a potential
approach to attenuate the behavioral and molecular effects of
stress-induced inﬂammation.40,41 Our ﬁndings strengthen the
role of caspase-1 as a potential therapeutic target aiming at
modulating inﬂammasome-mediated pathways in psychiatric
disorders.
Minocycline exerts anti-inﬂammatory and neuroprotective
effects in animal models of neurodegenerative disorders, neuro-
toxicity and brain injury as well as presents acute antidepressant-
like effects in the forced swim test by increasing climbing,
potentially through interaction with glutamatergic and/or nora-
drenergic systems.17,19,42,43 Its antidepressant-like effects might be
related to the protection of serotonergic and dopaminergic
circuitries.44,45 Consistent with this literature, we found that
minocycline prevented the exacerbation of depressive-like beha-
vior in the forced swim test following chronic restraint stress.
Given this ﬁnding, we suggest that minocycline may be valuable
in the treatment of MDD and other psychiatric disorders. Indeed,
two clinical trials investigating minocycline as a stand-alone or
adjuvant treatment in psychotic depression and schizophrenia
yielded promising results.46–49 Two studies have planned to
investigate the efﬁcacy of minocycline in MDD and bipolar
Figure 5. The effect of minocycline treatment, chronic restraint stress and their combination assessed at the level of individual taxa. Individual
minocycline effect on the (a) Turicibacter and (b) Biﬁdobacterium populations; synergistic effect of minocycline and chronic restraint stress on
the (c) Akkermansia, (d) Blautia and (e) Lachnospiraceae populations; and antagonistic effect of minocycline and chronic restraint stress on the
(f) Lactobacillus and (g) Anaerovorax populations. Signiﬁcant difference between treatment groups: *Po0.05, **Po0.01, ***Po0.001.
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disorder (Clinical Trials.gov identiﬁer NCT01574742 and
NCT01403662); yet, no recruitment data have been available.
Our ﬁndings show that the gut microbiota composition of mice
subjected to chronic restraint stress is signiﬁcantly altered when
compared with control mice. Subtle alterations in the Firmicutes/
Bacteroidetes ratio have already been described in studies of
irritable bowel syndrome patients (and correlated with clinical
depression and anxiety) and in animal models of hyper-
tension,50,51 and these two conditions are associated with chronic
low-grade inﬂammation.52,53 The deeper levels of comparison
were more informative, such as the levels of Biﬁdobacterium spp., a
genus associated with the suppression of inﬂammation through
inhibition of the nuclear factor-κB pathway,54 being signiﬁcantly
reduced in animals undergoing restraint. Such ﬁndings are
consistent with the notion that nuclear factor-κB is increased in
response to stress, and is a critical mediator of stress-induced
depressive-like behavior and stress-impaired neurogenesis.55
Furthermore, Allobaculum spp. were absent in restrained animals,
despite representing a substantial component of the microbiota in
control animals. Members of the genus Allobaculum include mucin
degraders, and their relative abundance is already known to be
inversely correlated with dietary-induced inﬂammation markers,
including leptin and IL-22.56,57 Chronic restraint also led to an
increase in the relative abundance of Lactobacillus spp., members
of which have been implicated in inﬂammasome activation
through stimulation of caspase-1-dependent IL-1β production by
macrophages.58 As such, it is interesting to speculate that the
increases in Lactobacillus spp. observed here when either restraint
or minocycline were used alone could be a contributing factor to
the increased IL-1β levels observed in depression and in animal
models of stress.1,59,60
Minocycline treatment also signiﬁcantly altered microbiota
composition, and the changes observed following minocycline
or restraint separately were not signiﬁcantly different. However,
when restrained mice were also treated with minocycline,
evidence of both synergistic and antagonistic effects on micro-
biota composition was observed. For example, Akkermansia,
Blautia and an uncultured member of the Lachnospiraceae family
were signiﬁcantly increased. This effect is notable given that
Akkermansia attenuates inﬂammation in adipose tissue through
induction of Foxp3 regulatory T cells, and suppression of IL-6 and
IL-1β.61–63 Moreover, a similar increase in Akkermansia was
reported in a study in which minocycline rebalanced the gut
microbiota in a rat model of hypertension.50 Lachnospiraceae is
one of the most abundant families of Firmicutes and is most often
associated with beneﬁcial production of short-chain fatty acids
from complex polysaccharides.64 An increase in Lachnospiraceae
relative abundance in minocycline-restraint animals is consistent
with changes in the gut microbiota of casp-1− /− mice.33
This study has several limitations. In this study, we chose
minocycline as a caspase-1 inhibiting compound to further
explore the relationship between the microbiota and host
behavior.27,28 Minocycline is an antibiotic and therefore it would
likely affect the gut microbiome regardless of caspase-1 inhibi-
tion.65 As minocycline has antidepressant effects, its inﬂuence on
the gut microbiome could be at least partially responsible for such
effects.21,44,45 Further work is required to elucidate the exact
mechanisms of gut microbiota–host interactions, including the
analysis of short-chain fatty acid production. The altered micro-
biome proﬁles we observed are likely to translate into alterations
in both metabolic proﬁles and host–microbe crosstalk, and to
investigate this is beyond the scope of the work presented here. It
could be argued that the withdrawal of food and water during the
restraint period might impact the microbiome.66 However,
because food was only withheld for short periods (4–6 h), we
contend that this will have had minimal impacts on the fecal
microbiome proﬁles. Mice were submitted twice to a battery of
behavioral test; exposure to one test could impact subsequent test
performance.34,67 However, we tried to minimize bias by
performing the tests from the least to the most invasive and by
giving the animals recovery time in between tests.34,67 Our chronic
restraint stress paradigm did not decrease sucrose preference,
which replicates published ﬁndings.68 Although this test is
considered a model of clinical anhedonia, it has highly variable
outcomes, even within the same facility.69
In a companion paper,70 we have shown three ﬁndings that are
highly complementary to the results reported here. (1) The
absence of gut microbiota in germ-free mice resulted in decreased
immobility time in the forced swimming test relative to
conventionally raised healthy control mice. (2) From clinical
sampling, the gut microbiotic compositions of healthy controls
were signiﬁcantly different from those of MDD patients. (3) Fecal
microbiota transplantation of germ-free mice with ‘depression
microbiota’ derived from MDD patients resulted in depression-like
behaviors compared with colonization with ‘healthy microbiota’
derived from healthy control individuals. Moreover, we showed
that mice harboring ‘depression microbiota’ primarily exhibited
disturbances of microbial genes and host metabolites involved in
carbohydrate and amino acid metabolism, indicating that the
development of depressive-like behaviors is mediated through the
host’s metabolism.70 Based on those ﬁndings, in conjunction with
the results presented here, we propose that the microbiota–gut–
brain axis is fully bidirectional, functioning in a manner through
which changes in microbiota affect behavior as shown in our
companion paper, whereas, as demonstrated here, changes in
behavior brought about (1) by chronic stress, (2) genetic
manipulation or (3) pharmacological intervention result in
changes in the gut microbiota.
In summary, our ﬁndings suggest that caspase-1 inhibition has a
protective effect on the stress response by modulating the
interface between stress and the gut microbiota. This supports the
concept of a microbiota–gut–inﬂammasome–brain axis in which
the gut microbiota exert some of its effects on brain function via
the inﬂammasome signaling platform that modulates inﬂamma-
tory pathways which will in turn alter brain function and affect
depressive- and anxiety-like behaviors. Taken together, a reduc-
tion of inﬂammasome bioactivity may represent a feasible and
direct therapeutic strategy in the treatment of MDD and other
neuropsychiatric disorders with inﬂammatory components. More-
over, direct modiﬁcation of the gut microbiota may offer new
opportunities to further mitigate these disorders, via indirect
modulation of inﬂammasome signaling. Future studies should
address the tolerability, safety and long-term effects of inﬂamma-
some modulation for the treatment of major depression.
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